Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Out-of-protocol concurrent use of cisplatin and radiation therapy in locally advanced cervical cancer: feasibility and survival
G. Mancebo1,*, A. Gil-Moreno2, R. Vergés Vergés3, J. M. Martínez-Palones Martínez-Palones2, M. A. Checa1, J. M. R. Carreras1, J. Giralt3, J. Xercavins2
1 Gynecology Oncology Unit, Department of Obstetrics and Gynecology
2 Hospital Universitari del Mar, Universitat Autònoma de Barcelona; Unit of Gynecologic Oncology, Department of Obstetrics and Gynecology
3 Hospital Materno-infantil Vall d’Hebron; and Unit of Radiation Oncology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona (Spain)
Eur. J. Gynaecol. Oncol. 2010, 31(1), 18–22;
Published: 10 February 2010
Purpose of investigation: We assessed the feasibility, response rates, and overall survival of patients with locally advanced cervical cancer treated with cisplatin-based chemotherapy during radiation therapy on an out-of-protocol basis. Methods: Sixty-nine consecutive newly diagnosed untreated patients with locally advanced cervical cancer who received chemoradiation between 1999 and 2003 were retrospectively reviewed. Treatment consisted in external beam radiation followed by one 137-cessium intracavitary application. Cisplatin was administered for six weeks during external beam radiation. Results: Treatment was well tolerated, although 52 patients presented some degree of acute adverse toxicity (gastrointestinal 65%, hematological 48%, genitourinary 10%). The 3-year survival rate was 61.8% (95% CI 54.5-69.0), with a mean 41.8 months (95% CI 35.7-48.3). Overall survival after adjusting by FIGO Stage IB2-IIA and IIB-IVA was 73.9% and 50%, respectively (p = 0.1839). Overall survival according to Stages IB2- IIb and III-IVA was 74.8% and 34.9%, respectively (p = 0.0376). Conclusion: In patients with locally advanced cervical cancer, adding a weekly regimen of cisplatin to standard pelvic radiation in an out-of-protocol basis is feasible, effective, and showed no unexpected toxicity.
Locally advanced cervical cancer
Pelvis radiation therapy